Firmagon® (Ferring)
Firmagon is the UK’s first GnRH blocker for the treatment of advanced prostate cancer and represents a significant pharmacologic advance over the current standard of care.
Following its win of the Firmagon (UK) account in 2008, Eurocom’s adaptation of the core global communications campaign helped to successfully launch this important uro-oncological brand to the UK’s healthcare community.
In addition to press advertising, salesforce support materials and congress activities, Eurocom has been responsible for the production of a patient DVD: ‘Progress for a Healthy Lifestyle’.
